Cita APA (7a ed.)

Kanevsky, D., Elgart, J. F., Zerga, M., Glancszpigel, M., & Morisset, P. (2022). Venetoclax in combination with obinutuzumab in first line chronic lymphocytic leukemia in Argentina: A cost-effectiveness analysis.

Cita Chicago Style (17a ed.)

Kanevsky, Diego, Jorge Federico Elgart, Marta Zerga, Mariana Glancszpigel, y Pierre Morisset. Venetoclax in Combination with Obinutuzumab in First Line Chronic Lymphocytic Leukemia in Argentina: A Cost-effectiveness Analysis. 2022.

Cita MLA (8a ed.)

Kanevsky, Diego, et al. Venetoclax in Combination with Obinutuzumab in First Line Chronic Lymphocytic Leukemia in Argentina: A Cost-effectiveness Analysis. 2022.